Luye Pharma Group Ltd. (DE:LUP)
FRANKFURT:LUP
LUP Stock Chart & Stats
€0.33
>-€0.01(-2.34%)
At close: 4:00 PM EST
€0.33
>-€0.01(-2.34%)
Day’s Range― - ―
52-Week Range€0.20 - €0.48
Previous CloseN/A
Volume0.00
Average Volume (3M)94.00
Market Cap
€809.70M
Enterprise Value€12.41B
Total Cash (Recent Filing)€8.88B
Total Debt (Recent Filing)€9.42B
Price to Earnings (P/E)10.5
Beta0.64
Next Earnings
Aug 27, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding3,994,515,900
10 Day Avg. Volume84
30 Day Avg. Volume94
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.47Price Target Upside43.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)€752.82M
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross and EBITDA margins indicate durable product-level pricing power and efficient manufacturing. That margin buffer supports reinvestment in R&D and commercialization, helping the company sustain operating profitability even if top-line growth is uneven over the next 2–6 months.
Improving LeverageA materially lower debt-to-equity and larger equity base reduce financial risk and increase capacity for capital allocation. Improved leverage provides more flexibility for funding pipelines, supporting M&A or partnerships without materially raising default or refinancing risk in the medium term.
Diversified Branded Portfolio & ChannelsA multi-therapeutic branded portfolio plus mixed self-operated and partner commercialization reduces single-product dependency and supports market access across geographies. This structural diversification strengthens revenue resilience and long-term market positioning against localized demand shocks.
Bears Say
Sharp Revenue DeclineA severe year-over-year revenue drop materially weakens the top-line base and raises questions about demand durability, product lifecycle timing, or market share loss. If sustained, lower scale can compress fixed-cost leverage and limit the company’s ability to fund growth initiatives over the medium term.
Volatile Free Cash FlowHistoric swings in free cash flow reduce predictability of internal funding for R&D, dividends, or acquisitions. Even with a 2025 rebound, inconsistent cash conversion (FCF conversion ~44% in 2025) limits confidence in steady cash returns and elevates financing risk for multi-year investments.
Low Return On EquityA low ROE despite healthy margins suggests the balance sheet and equity base are not being deployed efficiently to generate shareholder returns. Persistently weak ROE can indicate suboptimal capital allocation or low asset turnover, constraining long-term value creation.
Luye Pharma Group News
LUP FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was €0.20 and its highest was €0.48 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is €809.70M.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 81 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Mar 30, 2026. The company reported €0.01 earnings per share for the quarter, the consensus estimate of €0.01 by €0.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. does not currently pay dividends.
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is <0.01.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of €0.01 in its last earnings report, expectations of €0.01. Following the earnings report the stock price went up 6.154%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in DE:LUP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.47 (43.86% Upside)
€0.47 (43.86% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.45%
12-Months-Change
Fundamentals
Return on Equity
4.02%
Trailing 12-Months
Asset Growth
15.79%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
LUP Stock 12 Month Forecast
Average Price Target
€0.47
▲(43.86% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Options Prices
Currently, No data available
---